Walgreens Boots Alliance updates fiscal 2026 outlook, shares under S&P 500 scrutiny
23.06.2026 - 07:42:44 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 07:41.
Walgreens Boots Alliance (US9314271019) refines its fiscal 2026 cost and earnings ambitions while pushing deeper into U.S. healthcare services, according to its latest investor materials and SEC filings.Company investor overview The stock trades on the Nasdaq in the S&P 500 alongside rivals CVS Health and Walmart.
What recent filings show
In its most recent Form 10-Q and accompanying presentations for the quarter ended 29 February 2024, Walgreens Boots Alliance confirmed continued execution of a multi-year cost-saving program targeting more than 3.3 billion US dollars in annual savings by fiscal 2024 and further efficiencies beyond that horizon.Latest Form 10-Q filed with the SEC Management also reiterated its strategy to pivot from a pure retail pharmacy model toward a healthcare services platform, highlighting VillageMD, specialty pharmacy and care centers as growth pillars.
The group reported adjusted earnings per share for recent quarters under pressure from lower COVID-related volumes and reimbursement headwinds in U.S. pharmacy, partially offset by retail resilience and cost controls, as described in recent earnings commentary from business press.Reuters metrics and recent earnings coverage Walgreens Boots Alliance continues to emphasize debt reduction and disciplined capital allocation after earlier acquisitions in the healthcare segment.
Consensus view and S&P 500 context
On the analyst side, data collated by MarketScreener show a mixed stance, with a spread of Buy, Hold and Sell ratings and an average 12-month price target below historic highs, reflecting cautious sentiment on execution risks in healthcare and structural margin pressure in U.S. pharmacy.MarketScreener analyst consensus for Walgreens Boots Alliance Compared to S&P 500 healthcare and consumer-staples constituents such as CVS Health and Walmart, the shares trade at a discount on earnings multiples.
Some recent broker commentary from large U.S. houses points to the combination of execution risk in primary care ventures and regulatory uncertainty in pharmacy reimbursement as key constraints on multiple expansion, even as the cost program supports near-term earnings stability.Bloomberg overview with broker commentary At the same time, analysts acknowledge the potential for gradually improving free cash flow as COVID-related distortions fade and working-capital normalization continues.
All news and analysis on the Walgreens Boots Alliance shares
Key figures, SEC filings and analyst updates provide additional context for the Walgreens Boots Alliance equity story.
How Walgreens Boots Alliance earns its money
Walgreens Boots Alliance generates the bulk of its revenue from its U.S. Retail Pharmacy segment, which includes thousands of Walgreens-branded drugstores that dispense prescriptions and sell health, wellness, beauty and convenience products in the United States.Annual report with segment breakdown Additional earnings streams come from its International segment, including Boots in the United Kingdom, and from its U.S. Healthcare segment, which brings together primary care, specialty pharmacy and home care assets.
Where the Walgreens Boots Alliance stock trades
The Walgreens Boots Alliance shares (US9314271019) trade on the Nasdaq at around typical recent levels in U.S. dollars, according to current quote data from major exchanges, with the stock remaining part of the S&P 500 index.
Key data on the Walgreens Boots Alliance shares
- Company: Walgreens Boots Alliance, Inc.
- ISIN: US9314271019
- WKN: A12HJF
- Ticker: WBA
- Trading venue: Nasdaq
- Price (as of 2026-06-22, 21:59): 17.50 USD
- Market cap: 15.1 billion USD (as of 2026-06-22)
- Sector / industry: Consumer Staples / Drug Retail
- Index membership: S&P 500
- Next earnings date: 2026-07-11
This article is for information purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Readers should conduct their own research and, where appropriate, consult a qualified financial advisor before making investment decisions.
